ReviewNorth American journal of medical sciences2015
Clinical use of Insulin Degludec: Practical Experience and Pragmatic Suggestions.
Review in North American journal of medical sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Real-world comparative effectiveness of analogue and human insulin on glycemic control in children and adolescents with Type 1 diabetes in Lebanon using continuous glucose monitoring data.Journal of comparative effectiveness research · 2026Article
- Insulin degludec in pregestational diabetes: evidence and perspectives.Archives of medical sciences. Atherosclerotic diseases · 2024Article
- Practical Guidance on Basal Insulin Initiation and Titration in Asia: A Delphi-Based Consensus.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2022Article
- Review
- Flexibility in insulin prescription.Indian journal of endocrinology and metabolismArticle
- Insulin degludec and insulin degludec/insulin aspart in Ramadan: A single center experience.Indian journal of endocrinology and metabolismArticle
- Pragmatic use of insulin degludec/insulin aspart co-formulation: A multinational consensus statement.Indian journal of endocrinology and metabolismReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insulin degludec (IDeg) is an ultralong acting basal insulin. IDeg has unique pharmacokinetic and pharmacodynamic properties which allow once a daily dosage, at any time of the day. Its use is associated with a significantly lower risk of hypoglycemia. This review discusses the pragmatic use of IDeg, based on available evidence. A complete search of all nine original research papers (BEGIN® clinical trial program) pertaining to IDeg, listed in PubMed, was made to prepare this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.